Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection plus oral 5-FU-class chemotherapy for advanced digestive tract malignancies
ChiCTR-IPR-14005485Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection and fluorouracil in gastrointestinal neoplasia (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Clinical symptoms and Quality of life. Started Oct 2014; status: recruiting.
02
Drugs
compound kushen injectionfluorouracil
03
Conditions
gastrointestinal neoplasia
Beyond the preview
Go deeper on ChiCTR-IPR-14005485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005485.